Pharmacologically directed design of leukemia therapy.

Abstract

The ability to accumulate and retain the active metabolite of Ara-C varies widely among patients. Our studies demonstrate a significant correlation between clinical response and the pharmacokinetics of Ara-CTP in leukemia cells during therapy. Knowledge of the cellular pharmacology of Ara-CTP has been used to optimize dose rates and to design combination treatment schedules. An understanding of the cellular pharmacodynamics of other drugs is likely to be a useful parameter for planning treatment protocols.

• Authors: W Plunkett, V Heinemann, E Estey, M Keating
• Journal: Haematology and blood transfusion (Haematol Blood Transfus) Vol. 33 Pg. 610-3 ( 1990) ISSN: 0171-7111 [Print] Germany
• PMID: 2182451 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S., Review)

Chemical References

• Arabinonucleotides
• Cytarabine
• Arabinofuranosylcytosine Triphosphate
• Mitoxantrone

Topics

• Antineoplastic Combined Chemotherapy Protocols (pharmacology, therapeutic use)
• Arabinofuranosylcytosine Triphosphate (metabolism)
• Arabinonucleotides (metabolism)
• Cytarabine (administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
• Drug Evaluation
• Humans
• Leukemia (metabolism, pathology)
• Leukemia, Myeloid, Acute (drug therapy, metabolism)
• Mitoxantrone (administration & dosage, pharmacology)